Systematic Tuning of Heme Redox Potentials and Its Effects on O₂ Reduction Rates in a Designed Oxidase in Myoglobin

Ambika Bhagi-Damodaran,† Igor D. Petrik,† Nicholas M. Marshall,† Howard Robinson,‡ and Yi Lu†,‡

†Department of Chemistry, University of Illinois, Urbana–Champaign, Urbana, Illinois 61801, United States
‡Department of Biology, Brookhaven National Laboratory, Upton, New York 11973, United States

ABSTRACT: Cytochrome c Oxidase (CcO) is known to catalyze the reduction of O₂ to H₂O efficiently with a much lower overpotential than most other O₂ reduction catalysts. However, methods by which the enzyme fine-tunes the reduction potential (E°) of its active site and the corresponding influence on the O₂ reduction activity are not well understood. In this work, we report systematic tuning of the heme E° in a functional model of CcO in myoglobin containing three histidines and one tyrosine in the distal pocket of heme. By removing hydrogen-bonding interactions between Ser92 and the proximal His ligand and a heme propionate, and increasing hydrophobicity of the heme pocket through Ser92Ala mutation, we have increased the heme E° from 95 ± 2 to 123 ± 3 mV. Additionally, replacing the native heme b in the CcO mimic with heme a analogs, diacetyl, monoformyl, and diformyl hemes, that posses electron-withdrawing groups, resulted in higher E° values of 175 ± 5, 210 ± 6, and 320 ± 10 mV, respectively. Furthermore, O₂ consumption studies on these CcO mimics revealed a strong enhancement in O₂ reduction rates with increasing heme E°. Such methods of tuning the heme E° through a combination of secondary structure mutations and heme substitutions can be applied to tune E° of other heme proteins, allowing for comprehensive investigations of the relationship between E° and enzymatic activity.

Developing catalysts for fuel cells is a major focus of the current search for alternative energy sources, including catalysts for O₂ reduction, which remains the least efficient part of the fuel cells.¹⁰ The catalysts currently used for this reaction use precious platinum possessing relatively high overpotentials, which renders the catalyst energy inefficient. Thus, a major challenge in this area is to design efficient catalysts for O₂ reduction that use earth-abundant metal ions and employ low overpotentials.¹¹,¹² In a recent DFT study, Kjaergaard et al. developed a method for direct comparison between the best platinum-based catalysts with cytochrome c oxidase (CcO),¹² a biocatalyst that also reduces O₂ to H₂O under physiological conditions, and concluded that CcO is a better catalyst in terms of possessing much lower overpotential than current platinum-based catalysts. In addition, the CcO uses earth abundant metal ions (iron and copper) for catalysis. However, CcO is a large, (e.g., MW ≈ 200 kDa for bovine CcO) membrane protein that is not very stable and has much lower site density on electrochemical surfaces than small molecular catalysts.³ Therefore, an active area of research is to make biomimetic models of CcO that are much smaller, robust, and efficient in O₂ reduction.⁴

The catalytic site of CcO, where O₂ binding, activation, and reduction occurs, is a binuclear heme-copper center, which consists of a high spin heme and a copper (Cu₉) coordinated to three histidines, one of which is cross-linked to a tyrosine residue.⁵ The thermodynamic efficiency of O₂ reduction reaction in CcO’s is determined by the reduction potential (E°) of the catalytic heme iron.⁶ In order to maximize the energy efficiency of this reaction and reduce its overpotential, it is desirable to tune the heme E° such that it is as high and as close to that of O₂ (810 mV at pH7 vs SHE; all E° values reported in this work are also vs SHE)¹,¹³ However, while the E° of the heme (Fe³⁺/Fe²⁺ couple) is known to vary from −59 mV in cbb₃ oxidase to +365 mV in bovine heart CcO, the structural features responsible for such tuning of the E° is not well understood.⁶c–e In addition, while the role of heme E° in controlling electron transfer rates has been investigated extensively,⁶c its impact on O₂ reduction reactions, as in the case of CcO, remains unexplored. Understanding how the heme E° in CcO is tuned is important not only for designing efficient O₂ reduction catalysts with a lower overpotential but also for gaining insight into how different oxidases are able to tune their heme E°’s to match with those of their redox partners so that the electron flow is in the right direction for efficient O₂ reduction. A slight change of heme E° in terminal oxidases could potentially reverse the electron transfer direction, resulting in no or partial O₂ reduction. Such investigations are difficult in the native CcO due to the presence of multiple metal cofactors, which renders the spectroscopic and electrochemical characterization of the heme-copper center challenging. To overcome these difficulties, synthetic models have been made.⁴ However, to our knowledge, no study has investigated ways to fine-tune the E° of the catalytic heme and its effects on O₂ reduction activity in CcO or its synthetic models.

In a complementary approach to studying native CcOs and synthetic models, we have engineered a heme-copper center in a much smaller (MW = 17.4 kDa) O₂-binding protein sperm whale myoglobin (called Cu₉Mb),⁶a,b and showed that the presence of a Tyr in the active site through F33Y mutation (called F33Y-Cu₉Mb) resulted in a catalyst that reduces O₂ to
H$_2$O with hundreds of turnovers and minimal release of other reactive oxygen species (ROS) (Figure 1). In addition to being smaller, this functional mimic of CcO in Mb is much easier to purify and is free of other metal-binding sites as in CcO and, thus, represents an ideal candidate for investigating how to tune the $E^\circ$ of heme in a CcO-like environment and elucidating its impact on the O$_2$ reduction rates. Herein, we report the successful tuning of heme $E^\circ$ in F33Y-Cu$_b$Mb either through introducing a hydrophobic residue that perturbs hydrogen bonding (H-bonding) interactions in the proximal side of heme or by replacing the native heme $a$ with heme $b$ with heme $a$ analogs with high $E^\circ$, resulting in O$_2$ reduction catalysts with $E^\circ$ values within ~215 mV range. Additionally, we have also obtained a direct correlation between heme $E^\circ$ and oxidase activity of the CcO mimics.

The F33Y-Cu$_b$Mb was expressed and purified without a copper ion at the Cu$_b$ site. No copper ion was added in this work, as previous studies have shown that the presence of copper has little influence on the oxidase activity of F33Y-Cu$_b$Mb similar to the Cu$_b$-independent cytochrome $b$ oxidase. The $E^\circ$ of F33Y-Cu$_b$Mb was determined using a UV-vis spectroelectrochemical method as described previously, such a method was shown to be able to maintain the integrity of the protein while providing the benefit of direct monitoring of spectral transition from the oxidized form of the enzyme (Fe$^{3+}$) to its reduced form (Fe$^{2+}$) upon sweeping the potential (Figure 2A). The $E^\circ$ of F33Y-Cu$_b$Mb was obtained by global fitting of the spectral transition to the Nernst equation (black curve, Figure 2B; see Supporting Information (SI) for details). The $E^\circ$ of 95 ± 2 mV determined from this process lies between the ~59 mV in $cb_b$ oxidase and +365 mV in bovine CcO. This finding motivated us to explore ways to increase the $E^\circ$ of F33Y-Cu$_b$Mb to match that of CcO in order to lower the overpotential for the O$_2$ reduction reaction.

A previous study has shown that replacing the neutral Val68 residue in the distal pocket of human Mb with negatively charged Glu or Asp can decrease the $E^\circ$ by up to ~200 mV. Since this work, most mutations in Mb have resulted in a change of $E^\circ$ of much less than 200 mV; even fewer reports of mutations have been shown to increase the $E^\circ$. More importantly, since the distal pocket plays a critical role in binding and reducing O$_2$, it is even more difficult to tune the $E^\circ$ without affecting its oxidase activity. Under such constraints, we directed our attention to modifications on the proximal side of heme. Previous studies have demonstrated that increasing the hydrophobicity and tuning H-bonding around the secondary coordination sphere of the metal-binding site can increase the $E^\circ$ of metalloproteins. Applying the same methodologies toward Mb, we began to look for possible sites to alter on the proximal side of heme. NMR studies on WT Mb have suggested that the Ne proton of the proximal His93 ligand forms a weak H-bond with the lone pair of Ser92 (Figure 1). Therefore, disrupting this H-bond may increase the positive character of the Ne proton of His93, thereby reducing the overall electron donating ability of the imidazole ring towards the heme iron, leading to an increase in the heme $E^\circ$. Based on this hypothesis, we replaced the Ser92 with Ala, which being more hydrophobic may also raise the heme $E^\circ$ through preferential stabilization of Fe$^{2+}$ over Fe$^{3+}$. The UV-vis spectra of both oxidized and reduced S92A-F33Y-Cu$_b$Mb are very similar to those of F33Y-Cu$_b$Mb (Table S1), suggesting that the S92A mutation exerted minimal perturbation on the protein structure. A 1.64 Å resolution crystal structure of this mutant indicates that the S92A mutation did indeed eliminate the H-bonding interactions between Ser92, His93, and heme propionate, resulting in a negatively charged propionate moving away from the mutation site of Ser92 and heme iron (Figures 1, S1). The $E^\circ$ of S92A-F33Y-Cu$_b$Mb was found to be 123 ± 3 mV (Figures 2B, S2), suggesting that introducing the hydrophobic residue and the associated changes in the H-bonding interactions are responsible for the observed enhancements in the heme $E^\circ$. This finding correlates well with a recent study in $cb_b$ oxidase, in which perturbing H-bonding interactions of proximal histidine ligand of catalytic heme $b_1$ lead to a variation in $E^\circ$ values by ~40 mV.

While the increase of $E^\circ$ from 95 to 123 mV is encouraging, it is still much less than the 365 mV of bovine CcO. To increase the $E^\circ$ further, we noticed a major difference between the heme in our protein model in Mb and that in bovine CcO: while heme $b$ is present in our Mb model system, various A- and B-
type CcOs with high $E^\circ$ values use heme a (Figure 3). The presence of an electron-withdrawing formyl group conjugated to the porphyrin ring in heme a can destabilize the oxidized form of the heme and thus increase the heme $E^\circ$. For example, Gibney and co-workers replaced the heme $b$ in a $de novo$ designed $\alpha$-helical bundle protein with heme $a$ and observed an increase in $E^\circ$ value by 157 mV. While this result is exciting in the $de novo$ designed protein, replacing the heme $b$ with heme $a$ in Mb resulted in a misfolded protein, due to the lack of space in the Mb to accommodate the C14 farnesyl chain (Figure 3).

Based on the above comparison and findings, we embarked on a systematic study of increasing heme $E^\circ$ by using a different strategy of replacing the native heme $b$ in Mb with heme $a$ analogues of high $E^\circ$. Mb is an ideal system for such a strategy because the heme $b$ can be readily extracted and replaced with non-native heme cofactors of similar structures and sizes.

We therefore decided to replace heme $b$ in F33Y-CuMb with diacetyl (DA-), monofomyl (MF-), and difomyl (DF-) derivatives of heme that are similar in structure to that of heme $b$ in Mb but resemble heme $a$ in electronic properties (Figure 3). The extraction of heme $b$ and incorporation of the above three heme analogs into F33Y-CuMb were carried out using the protocol reported previously with minimal modification (see SI).

The UV–vis absorption spectra of the three F33Y-CuMb variants reveal an intense Soret band around 400 nm, along with $\alpha$ and $\beta$ transitions in the visible region (Table S1), which are typical of the oxidized form of Mb. The secondary structures of the heme substituted proteins were confirmed by circular dichroism spectra, which showed minima at 222 and 209 nm, consistent with well folded $\alpha$ helical protein containing native heme $b$ (Figure S3).

Having confirmed that the F33Y-CuMb variants were well-folded in the presence of non-native heme cofactors, we carried out UV–vis spectrophotometric and electrochemical measurements to determine their $E^\circ$’s. The spectrophotometric reduction of each of these three variants exhibited a clean transition from its oxidized to reduced form (Figure S2), and the global fit of data to the Nernst equation (Figure 2B) revealed $E^\circ$ values of 175 ± 5, 210 ± 6, and 320 ± 10 mV for F33Y-CuMb (DA-heme), (MF-heme), and (DF-heme), respectively. Thus, by incorporation of non-native heme cofactors, we have been able to increase the $E^\circ$ for F33Y-CuMb by approximately 80, 115, and 215 mV respectively, with the $E^\circ$ of the F33Y-CuMb with DF-heme (320 ± 10 mV) being very close to that of bovine CcO (365 mV).

Finally, having achieved rational tuning of the heme $E^\circ$ in F33Y-CuMb, we explored the effect of heme $E^\circ$ on its oxidase activity. The rates of O2 reduction by these F33Y-CuMb variants in the presence of the reductant ascorbate ($E^\circ$ = 96 mV) and redox mediator, $N,N,N',N'$-tetramethyl-p-phenylene-diamine (TMPD) ($E^\circ$ = 270 mV) were measured using an O2 electrode and a protocol reported previously for both native CcOs and their models. For the oxidase to function efficiently, it is required to perform a complete 4e$^-$ reduction of O2 into H2O; any incomplete reduction, such as 1e$^-$ or 2e$^-$ reduction of O2 to superoxide (O2$^-$) or peroxide (O2$^{2-}$) will result in not only lower efficiency in O2 reduction, but also ROS that is detrimental to the biomolecules in living cells or components in fuel cells. Therefore, we measured the ratio of H2O formation with respect to O2$^-$ and O2$^{2-}$ as previously reported, by repeating the O2 reduction experiments in the presence of superoxide dismutase and catalase, which selectively react with O2$^-$ and O2$^{2-}$, respectively (see SI for details).

Interestingly, the oxidase activity of the F33Y-CuMb variants increase with increasing $E^\circ$ of the heme, while the ratio of H2O produced with respect to the ROS remains almost constant (Figure 4A). The F33Y-CuMb (DF-heme), with an $E^\circ$ value of 320 mV, exhibits an over 5-fold increase in oxidase activity as compared to F33Y-CuMb with heme $b$. These results strongly suggest that increasing the heme $E^\circ$ makes the heme iron a better acceptor of electrons from the redox mediator, resulting in a higher driving force for a faster O2 reduction reaction.

**Figure 4.** (A) Rates of O2 reduction to form either H2O (blue) or ROS (red) catalyzed by 6 µM F33Y-CuMb variants in 100 mM phosphate buffer (pH6) containing 258 µM O2, 1 mM TMPD, and 10 mM ascorbate. (B) O2 reduction turnover measured during the stepwise addition of O2 for F33Y-CuMb and its (MF-heme) and (DF-heme) variants.
Furthermore, all the three tested enzymes (F33Y-CuMb, F33Y-CuMb (MF-heme), and F33Y-CuMb (DF-heme)) are capable of performing hundreds of turnovers, with the more active enzyme possessing the highest \( E^o \) (F33Y-CuMb (DF-heme)), performing more than 1000 turnovers under similar conditions and over the same time (Figure 4B). In control experiments, we also replaced the heme \( b \) in WTMb with DA-heme and DF-heme and found that such a replacement increased the \( E^o \) value of WTMb from 61 ± 2 mV to 154 ± 3 mV and 268 ± 7 mV respectively (Figure SS). Thus, the increase in heme \( E^o \) in WTMb shows parallel results with the F33Y-CuMb mutant. Interestingly, even though the increase in heme \( E^o \) leads to an increase in overall \( O_2 \) reduction rates for both WTMb and F33Y-CuMb, the percentage of complete \( O_2 \) reduction to \( H_2O \) shows opposite trends. While, for WTMb variants, the higher heme \( E^o \) results, the higher heme \( E^o \) results in more \( H_2O \) formation (Figure SS). This comparison strongly suggests the importance of the H-bonding network formed by distal mutations (that form the Cu[site and Tyr]) and associated H2O molecules (Figure S1, crystal structure of F33Y-CuMb) to control the protonation/deprotonation of \( O_2 \) for its reduction to \( H_2O \).

In summary, we have demonstrated effective methods to systematically increase the \( E^o \) of the heme in a functional model of CrCox in myoglobin, by up to ~215 mV. The methods include removing H-bonding interactions and increasing hydrophobicity in the proximal side of the heme and replacing the native heme \( b \) with heme \( a \) analogs that possess electron-withdrawing groups that possess higher \( E^o \). A correlation of the heme \( E^o \) with the \( O_2 \) reduction activity is also established (Figure 5). The methods of tuning \( E^o \) shown in this study can be applied to other heme proteins allowing systematic investigation of the relationship between heme \( E^o \) and other enzymatic activities.

### Supporting Information

Experimental details, spectroelectrochemical measurements, and X-ray crystallography of F33Y-CuMb and its variants. This material is available free of charge via the Internet at http://pubs.acs.org.

### Notes

The authors declare no competing financial interest.

### ACKNOWLEDGMENTS

We thank Anoop R. Damodaran and Prof. Robert B. Gennis for helpful discussions. This report is based on work supported by the US National Institute of Health (GM062211).

### REFERENCES

(1) (a) Cracknell, J. A.; Vincent, K. A.; Armstrong, F. A. Chem. Rev. 2008, 108, 2439. (b) Jeon, I.-Y.; Choi, H.-J.; Choi, M.; Seo, J.-M.; Jung, S.-M.; Kim, M.-J.; Zhang, S.; Zhang, L.; Xia, Z.; Dai, L.; Park, N.; Back, J.-B. Sci. Rep. 2013, 3, 1810. (c) Dutta, A.; Roberts, J. A. S.; Shaw, W. J. Angew. Chem., Int. Ed. 2014, 126, 1. (d) Kjaergaard, C. H.; Rossmeisl, J.; Norskov, J. K. Inorg. Chem. 2010, 49, 3567.

(2) (a) Egawa, T.; Yeh, S. R.; Rousseau, D. L. PLoS One 2013, 8 (S), 63669. (b) Ferguson-Miller, S.; Babcock, G. T. Chem. Rev. 1996, 96, 2889. (c) Borisov, V. B.; Gennis, R. B.; Henp, J.; Verkhovsky, M. I. Biochim. Biophys. Acta, Bioenerg. 2011, 1807, 1398. (d) Wikström, M.; Verkhovsky, M. I. Biochim. Biophys. Acta 2007, 1767, 1200.

(3) Friedrich, M. G.; Plum, M. A.; Santonico, M. G.; Kirste, V. U.; Knoll, W.; Ludwig, B.; Naumann, R. L. C. Biophys. J. 2008, 95, 1500.

(4) (a) Naruta, Y.; Takao, S.; Tani, F.; Tachi, Y.; Nobuo, K.; Nobuhumi, J. Inorg. Biochem. 2001, 83, 239. (b) Kim, E.; Chufan, E. E.; Kamaraj, K.; Karlin, K. D. Chem. Rev. 2004, 104, 1077.

(5) (a) Pawate, A. S.; Morgan, J.; Nanslauer, A.; Mills, D.; Brzezinski, P.; Ferguson-Miller, S.; Gennis, R. B. Biochemistry 2002, 41, 13417. (b) Jancura, D.; Antalik, M.; Berka, V.; Palmer, G.; Fabian, M. J. Biol. Chem. 2006, 281, 20003. (c) Rauhmanaki, Y.; Bloch, D. A.; Verkhovsky, M. I.; Wikström, M. J. Biol. Chem. 2009, 284, 11301. (d) Dutton, P. L.; Wilson, D. F.; Lee, C. P. Biochemistry 1970, 9, 5077. (e) Ellis, W. R.; Wang, H.; Blair, D. F.; Gray, H. B.; Chan, S. I. Biochemistry 1986, 25, 161. (f) Winkler, J. R.; Gray, H. Chem. Rev. 2013, 114, 3369. (g) Xiong, P.; Nocek, J. M.; Yura-Weiss, J.; Lockard, J. V.; Wasielewski, M. R.; Hoffman, B. M. Science 2010, 330, 1075.

(6) (a) Sigman, J. A.; Kwok, B. C.; Lu, Y. J. Am. Chem. Soc. 2000, 122, 8192. (b) Sigman, J. A.; Kim, H. K.; Zhao, X.; Carey, J. R.; Lu, Y. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 3639. (c) Yu, Y.; Mukherjea, A.; Nilges, M. J.; Hosseinizadeh, P.; Miner, K. D.; Lu, Y. J. Am. Chem. Soc. 2014, 136, 1174. (d) Miner, K. D.; Mukherjea, A.; Gao, Y.-G.; Null, E. L.; Petrik, I. D.; Zhao, X.; Yeung, N.; Robinson, H.; Lu, Y. Angew. Chem., Int. Ed. 2012, 51, S589. (e) Liu, X.; Yu, Y.; Hu, C.; Zhang, W.; Lu, Y.; Wang, J. Angew. Chem., Int. Ed. 2012, 51, 43. (f) Zhao, X.; Nilges, M. J.; Lu, Y. Biochemistry 2005, 44, 6559.

(7) (a) Varadarajan, R.; Zewert, T. E.; Gray, H. B.; Boxer, S. G. Science 1999, 283, 699. (b) Zheng, Z.; Günner, A. R. Proteins 2009, 75, 719. (c) Liu, J.; Chakraborty, S.; Hosseinizadeh, P.; Yu, Y.; Tian, S.; Petrik, I.; Bhagi, A.; Lu, Y. Chem. Rev. 2014, 114, 4366. (d) Reedy, C. J.; Elvekrog, M. M.; Gibney, B. R. Nucleic Acids Res. 2008, 36, D307. (e) Marshall, N. M.; Garner, D. K.; Wilson, T. D.; Gao, Y.-G.; Robinson, H.; Nilges, M. J.; Lu, Y. Nature 2009, 462, 113. (f) Shirai, Y.; Izuka, T.; Marubayashi, K.; Ogura, T.; Kitagawa, T.; Balasubramanian, S.; Boxer, S. G. Biochemistry 1994, 33, 14986. (g) Decatur, S. M.; Belcher, K. L.; Rickert, P. K.; Franzen, S.; Boxer, S. G. Biochemistry 1999, 38, 11086.

(8) (a) Zhuang, J. Y.; Amoroso, J. H.; Kinloch, R.; Dawson, J. H.; Baldwin, M. J.; Gibney, B. R. Inorg. Chem. 2006, 45, 4685. (b) Zhuang, J.; Reddi, A. R.; Wang, Z.; Khodaverdian, B.; Hegg, E. L.; Gibney, B. R. Biochemistry 2006, 45, 12530. (c) Larsen, R. W.; Nunez, D. J.; Macleod, J.; Shiemko, A. K.; Masser, S. M.; Nguyen, H. H.; Ondrias, M. R.; Chan, S. I. J. Inorg. Biochem. 1992, 48, 21.

(9) (a) Watanabe, Y. Curr. Opin. Chem. Biol. 2002, 6, 208. (b) Lim, A. R.; Sishta, B. P.; Mauk, A. G. J. Inorg. Biochem. 2006, 100, 2017. (c) Wang, N.; Zhao, X.; Lu, Y. J. Am. Chem. Soc. 2005, 127, 16541. (d) Mehl, A. F.; Crawford, M. A.; Zhang, L. J. Chem. Educ. 2009, 86, 600.